Noveris Health Sciences Inc. MYCOF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 666.80K | 358.80K | 386.90K | 849.50K | 1.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 661.30K | 327.60K | 355.70K | -1.08M | 196.70K |
| Operating Income | -661.30K | -327.60K | -355.70K | 1.08M | -196.70K |
| Income Before Tax | 1.16M | 1.13M | 2.10M | 1.62M | 109.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.16 | 1.13 | 2.10 | 1.62 | 0.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.16M | 1.13M | 2.10M | 1.62M | 109.10K |
| EBIT | -661.30K | -327.60K | -355.70K | 1.08M | -196.70K |
| EBITDA | -- | -- | -- | 1.44M | 239.30K |
| EPS Basic | 1.80 | 1.80 | 1.70 | 1.32 | 0.09 |
| Normalized Basic EPS | -0.17 | -0.22 | -0.34 | 0.35 | -0.41 |
| EPS Diluted | 1.80 | 1.80 | 1.70 | 1.32 | 0.09 |
| Normalized Diluted EPS | -0.17 | -0.22 | -0.34 | 0.35 | -0.41 |
| Average Basic Shares Outstanding | 76.89M | 19.58M | 4.94M | 4.94M | 4.94M |
| Average Diluted Shares Outstanding | 76.89M | 19.58M | 4.94M | 4.94M | 4.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |